Significance of the Phase III FLAURA Study in EGFR+ NSCLC

September 11, 2017
Joshua Bauml, MD

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer.